Literature DB >> 24963041

Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system.

Hong Wang1, Fenglin Cao2, Jinmei Li1, Limin Li1, Yong Li3, Ce Shi1, Wenjia Lan1, Dandan Li1, Hui Zhao1, Ying Zhang1, Zhuo Zhang1, Xiuhua Liu1, Ran Meng1, Baofeng Yang1, Jin Zhou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24963041      PMCID： PMC4168355          DOI： 10.1182/blood-2014-04-568121

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  CNS relapse in acute promyeloctyic leukemia.

Authors:  Elizabeth Housman; Priscilla Chang; Steven W Lane; Russell Blinder; Ilene Galinsky; Santosh Kesari; Vincent T Ho; Richard M Stone; Ann Mullally
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia.

Authors:  Z Jin; M Ran; Z Man
Journal:  Haematologica       Date:  2007-09       Impact factor: 9.941

3.  Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.

Authors:  Jin Zhou; Yingmei Zhang; Jinmei Li; Xiaoxia Li; Jinxiao Hou; Yanqiu Zhao; Xiuhua Liu; Xueying Han; Longhu Hu; Shuye Wang; Yanhong Zhao; Ying Zhang; Shengjin Fan; Chengfang Lv; Limin Li; Lingling Zhu
Journal:  Blood       Date:  2009-12-22       Impact factor: 22.113

4.  Central nervous system relapse in a patient with acute promyelocytic leukaemia: does the risk stratification matter?

Authors:  Deniz Goren Sahin; Eren Gunduz; Olga Meltem Akay; Zafer Gulbas
Journal:  BMJ Case Rep       Date:  2013-06-06

5.  Various tolerances to arsenic trioxide between human cortical neurons and leukemic cells.

Authors:  Jin Zhou; Ran Meng; Xinhua Sui; Wenbin Li; Baofeng Yang
Journal:  Sci China C Life Sci       Date:  2006-12

6.  Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.

Authors:  Wing-Yan Au; Sidney Tam; Bonnie M Fong; Yok-Lam Kwong
Journal:  Blood       Date:  2008-08-14       Impact factor: 22.113
  6 in total
  13 in total

1.  Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.

Authors:  E Lengfelder; F Lo-Coco; L Ades; P Montesinos; D Grimwade; B Kishore; S M Ramadan; M Pagoni; M Breccia; A J G Huerta; A M Nloga; J D González-Sanmiguel; A Schmidt; J-F Lambert; S Lehmann; E Di Bona; B Cassinat; W-K Hofmann; D Görlich; M-C Sauerland; P Fenaux; M Sanz
Journal:  Leukemia       Date:  2015-01-28       Impact factor: 11.528

Review 2.  Isolated Central Nervous System (CNS) Relapse in Paediatric Acute Promyelocytic Leukaemia: A Systematic Review.

Authors:  Smeeta Gajendra; Rashmi Ranjan Das; Rashi Sharma
Journal:  J Clin Diagn Res       Date:  2017-03-01

3.  Effects of Arsenic Trioxide on Minor Progressive High-Grade Osteosarcoma of the Extremities Metastatic to the Lung: Results of 39 Patients Treated in a Single Institution.

Authors:  Lu Xie; Wei Guo; Xiaodong Tang; Yi Yang; Jie Xu
Journal:  Case Rep Oncol       Date:  2016-10-17

4.  Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy.

Authors:  Claudia Paret; Johanna Theruvath; Alexandra Russo; Bettina Kron; Khalifa El Malki; Nadine Lehmann; Arthur Wingerter; Marie A Neu; Aslihan Gerhold-Ay; Wolfgang Wagner; Clemens Sommer; Torsten Pietsch; Larissa Seidmann; Jörg Faber
Journal:  Oncotarget       Date:  2016-12-13

5.  Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report.

Authors:  Xuzhao Zhang; Jinliang Chen; Weiqin Wang; Xian Li; Yanbin Tan; Xiaohong Zhang; Wenbin Qian
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

6.  Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.

Authors:  Tilmann Bochtler; Stefan Fröhling; Wilko Weichert; Volker Endris; Christian Thiede; Barbara Hutter; Michael Hundemer; Anthony D Ho; Alwin Krämer
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-09

7.  Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy.

Authors:  Claudia Paret; Alexandra Russo; Henrike Otto; Arnulf Mayer; Sebastian Zahnreich; Wolfgang Wagner; David Samuel; David Scharnhorst; David A Solomon; Girish Dhall; Kenneth Wong; Hannah Bender; Francesca Alt; Arthur Wingerter; Marie A Neu; Olaf Beck; Dirk Prawitt; Stefan Eder; Nicole Henninger; Khalifa El Malki; Nadine Lehmann; Nora Backes; Lea Roth; Larissa Seidmann; Clemens Sommer; Marc A Brockmann; Gundula Staatz; Heinz Schmidberger; Jörg Faber
Journal:  Oncotarget       Date:  2017-12-11

8.  Metabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells.

Authors:  Xiaoling Zhang; Jing Yang; Minjian Chen; Lei Li; Fei Huan; Aiping Li; Yanqing Liu; Yankai Xia; Jin-Ao Duan; Shiping Ma
Journal:  Oncotarget       Date:  2016-07-19

9.  Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.

Authors:  Xinxin Zhang; Huiyun Zhang; Limei Chen; Mengchang Wang; Jieying Xi; Xin Liu; Ming Xie; Dengzhe Li; Ekamjyot Singh Gulati; Sha Gong; Huaiyu Wang
Journal:  Trials       Date:  2018-09-05       Impact factor: 2.279

Review 10.  Autophagy in Cancer Cell Death.

Authors:  Benedikt Linder; Donat Kögel
Journal:  Biology (Basel)       Date:  2019-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.